Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis

Autor: Hideto Kameda, Akimichi Morita, Hidemi Nakagawa, Shigetoshi Sano, Yoshiya Tanaka, Tomoko Kashiwagi, Takeshi Kawaberi, Atsuo Taniguchi, Junko Kimura
Rok vydání: 2018
Předmět:
Male
030213 general clinical medicine
medicine.medical_treatment
Efficiency
Severity of Illness Index
0302 clinical medicine
Japan
Absenteeism
Pharmacology (medical)
Prospective Studies
BASDAI
Original Research
education.field_of_study
General Medicine
Middle Aged
TNF inhibitor
C-Reactive Protein
Treatment Outcome
030220 oncology & carcinogenesis
Psoriatic arthritis
Work disability
Female
Postmarketing surveillance study
medicine.drug
musculoskeletal diseases
Adult
medicine.medical_specialty
Work productivity
Population
Activity impairment
03 medical and health sciences
Rheumatology
Psoriasis Area and Severity Index
Internal medicine
medicine
Adalimumab
Product Surveillance
Postmarketing
Humans
Psoriasis
education
Work Performance
Ankylosing spondylitis
business.industry
Arthritis
Psoriatic
medicine.disease
business
Zdroj: Advances in Therapy
ISSN: 1865-8652
Popis: Introduction This study investigated the effectiveness of adalimumab treatment in improving Work Productivity and Activity Impairment (WPAI) in patients with psoriatic arthritis (PsA) in real-world settings in Japan. Methods This 24-week, single-arm, postmarketing surveillance study (2014–2017), conducted at 75 centers in Japan, enrolled adalimumab-naïve patients (paid workers, including part-time) meeting ClASsification criteria for Psoriatic ARthritis (CASPAR). The primary endpoint was improvement in overall work impairment (OWI) scores from baseline to week 24. Secondary endpoints included changes in WPAI-PsA (OWI, absenteeism, presenteeism, and activity impairment), Psoriasis Area and Severity Index (PASI), psoriatic arthritis screening and evaluation (PASE) scores, Disease Activity Scores in 28 joints using C-reactive protein (DAS28[CRP]), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, Health Assessment Questionnaire-Disability Index (HAQ-DI) scores, and PASI75/90 and American College of Rheumatology (ACR) 20/50/70 rates. Results In the effectiveness population (n = 106; 72.6% men; mean ± standard deviation [SD] age, 49.3 ± 10.7 years), OWI scores significantly improved (mean ± SD change, − 25.2 ± 35.3; p
Databáze: OpenAIRE
Externí odkaz: